{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:32:36Z","timestamp":1792096356753,"version":"4.4.0"},"reference-count":40,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:00:00Z","timestamp":1631318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, reactivation of varicella zoster virus (VZV) has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of VZV reactivation following COVID-19 vaccination. We identified 12 eligible articles which included 91 patients with herpes zoster (HZ) following COVID-19 vaccination. Hypertension was the main comorbidity present in 18% of patients (16\/91). Additionally, 13% of patients (12\/91) had an autoimmune condition with rheumatoid arthritis being the most common (4\/12). Moreover, 10% of patients (9\/91) were receiving immunosuppressants. The dermatomal distribution of skin lesions varied among patients, with the mammary region being most affected. On average, symptoms developed 5.8 days post-vaccination irrespective of dose and treatment with oral valacyclovir as a monotherapy was employed in most patients (23\/91). HZ is possibly a condition clinicians may expect to encounter in patients receiving COVID-19 vaccines. While causality has not yet been established increased awareness and early recognition of the disorder would be crucial for the optimal management of these patients.<\/jats:p>","DOI":"10.3390\/vaccines9091013","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T21:48:01Z","timestamp":1631483281000},"page":"1013","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports"],"prefix":"10.3390","volume":"9","author":[{"given":"Konstantinos","family":"Katsikas Triantafyllidis","sequence":"first","affiliation":[{"name":"Department of Nutrition & Dietetics, Musgrove Park Hospital, Taunton & Somerset NHS Foundation Trust, Taunton TA1 5DA, UK"},{"name":"Society of Meta-Research and Biomedical Innovation, London W12 0BZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1037-1983","authenticated-orcid":false,"given":"Panagiotis","family":"Giannos","sequence":"additional","affiliation":[{"name":"Society of Meta-Research and Biomedical Innovation, London W12 0BZ, UK"},{"name":"Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran Tariq","family":"Mian","sequence":"additional","affiliation":[{"name":"Brighton and Sussex Medical School, Falmer BN1 9PX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kyrtsonis","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Croydon University Hospital, Croydon, London CR7 7YE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6681-8479","authenticated-orcid":false,"given":"Konstantinos S.","family":"Kechagias","sequence":"additional","affiliation":[{"name":"Society of Meta-Research and Biomedical Innovation, London W12 0BZ, UK"},{"name":"Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London W12 0NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmv.25678","article-title":"Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle","volume":"92","author":"Lu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","article-title":"The socio-economic implications of the coronavirus pandemic (COVID-19): A review","volume":"78","author":"Nicola","year":"2020","journal-title":"Int. J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41591-021-01435-1","article-title":"A French cohort for assessing COVID-19 vaccine responses in specific populations","volume":"27","author":"Loubet","year":"2021","journal-title":"Nat. Med."},{"key":"ref_5","unstructured":"Johnson, J. (2021). Johnson & Johnson COVID-19 Vaccine Authorized by US FDA For Emergency Use-First Single-Shot Vaccine in Fight Against Global Pandemic, Johnson & Johnson."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 Vaccine: A comprehensive status report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M.H., Turner, D.L., and Turner, R.J. (2021). Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines, 9.","DOI":"10.2139\/ssrn.3812422"},{"key":"ref_13","first-page":"e212","article-title":"Cutaneous manifestations in COVID-19: A first perspective","volume":"34","author":"Recalcati","year":"2020","journal-title":"J. Eur. Acad. Derm. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/jocd.14035","article-title":"Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?","volume":"20","author":"Bostan","year":"2021","journal-title":"J. Cosmet. Derm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: A meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_18","first-page":"581","article-title":"Guidelines for submitting adverse event reports for publication","volume":"16","author":"Kelly","year":"2007","journal-title":"Pharm. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.7774\/cevr.2021.10.2.198","article-title":"A rare case of shingles after COVID-19 vaccine: Is it a possible adverse effect?","volume":"10","author":"Aksu","year":"2021","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Alpalh\u00e3o, M., and Filipe, P. (2021). Herpes Zoster following SARS-CoV-2 vaccination\u2013a series of 4 cases. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.17555"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Arora, P., Sardana, K., Mathachan, S.R., and Malhotra, P. (2021). Herpes zoster after inactivated COVID-19 vaccine: A cutaneous adverse effect of the vaccine. J. Cosmet. Derm.","DOI":"10.1111\/jocd.14268"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Catal\u00e0, A., Mu\u00f1oz-Santos, C., Galv\u00e1n-Casas, C., Roncero Riesco, M., Revilla Nebreda, D., Sol\u00e1-Truyols, A., Giavedoni, P., Llamas-Velasco, M., Gonz\u00e1lez-Cruz, C., and Cubir\u00f3, X. (2021). Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases. Br. J. Derm.","DOI":"10.1111\/bjd.20639"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chiu, H.-H., Wei, K.-C., Chen, A., and Wang, W.-H. (2021). Herpes zoster following COVID-19 vaccine: A report of three cases. QJM Int. J. Med., hcab208.","DOI":"10.1093\/qjmed\/hcab208"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1002\/jmv.27036","article-title":"Herpes zoster emergence following mRNA COVID-19 vaccine","volume":"93","author":"Eid","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Furer, V., Zisman, D., Kibari, A., Rimar, D., Paran, Y., and Elkayam, O. (2021). Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A case series. Rheumatology.","DOI":"10.1093\/rheumatology\/keab345"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/jocd.14210","article-title":"20 Post-COVID-19 vaccine-related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media","volume":"20","author":"Lee","year":"2021","journal-title":"J. Cosmet. Derm."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Psichogiou, M., Samarkos, M., Mikos, N., and Hatzakis, A. (2021). Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2. Vaccines, 9.","DOI":"10.3390\/vaccines9060572"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.04.014","article-title":"Varicella-Zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases","volume":"12","author":"Chicharro","year":"2021","journal-title":"Jaad Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tessas, I., and Kluger, N. (2021). Ipsilateral Herpes Zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine. J. Eur. Acad. Derm. Venereol.","DOI":"10.1111\/jdv.17422"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/fvl.10.90","article-title":"Varicella zoster virus latency","volume":"6","author":"Eshleman","year":"2011","journal-title":"Future Virol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Depledge, D.P., Sadaoka, T., and Ouwendijk, W.J. (2018). Molecular aspects of varicella-zoster virus latency. Viruses, 10.","DOI":"10.20944\/preprints201806.0036.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun. Ageing"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1017\/S0950268802007793","article-title":"The role of solar ultraviolet irradiation in zoster","volume":"129","author":"Borkowski","year":"2002","journal-title":"Epidemiol. Infect."},{"key":"ref_34","unstructured":"Medicines & Healthcare Products Regulatory Agency (2021, July 24). Coronavirus Vaccine Weekly Summary of Yellow Card Reporting. gov.uk, Available online: https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(99)00623-6","article-title":"Reactivation of herpesvirus infections after vaccinations?","volume":"353","author":"Walter","year":"1999","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jinf.2020.04.012","article-title":"Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China","volume":"81","author":"Bo","year":"2020","journal-title":"J. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s13555-021-00549-1","article-title":"Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review","volume":"11","author":"Parikh","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fcimb.2012.00122","article-title":"Toll-like receptor sensing of human herpesvirus infection","volume":"2","author":"West","year":"2012","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/9\/1013\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:01:10Z","timestamp":1760166070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/9\/1013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["vaccines9091013"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9091013","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,11]]}}}